Revolution Medicines presents $198 million in Q3 RASONQUE launch revenue

Bitget2026/11/04 22:51

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Revolution Medicines reported $198 million in third-quarter RASONQUE revenue, reflecting approximately five weeks of commercial availability.
More than 5,000 US patients received commercial treatment; functional access exceeded 90% of US pancreatic cancer covered lives.
RASONQUE reduced death risk by 60% versus chemotherapy in previously treated metastatic pancreatic cancer; median overall survival reached 13.2 months.
European regulators issued a positive CHMP opinion for daraxonrasib; launch preparations are advancing in Japan.
Cash and investments totaled $3.7 billion at September 30, 2026; full-year GAAP operating expenses are projected at $2.1 billion–$2.2 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Revolution Medicines presents $198 million in Q3 RASONQUE launch revenue

You may also like

Crypto prices